Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany

We love to hear from our listeners. Send us a message.

Join Matt Pillar for a conversation with Carine Boustany, PharmD and SVP, US Research Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim.  On this episode of the Business of Biotech,  we walk through the story leading up to the recent approval of spesolimab.  In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. Dr. Boustany shares the antibody's fortuitous discovery, the challenges her team faced on the path to approval, and how those challenges were overcome. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/